Answers are grounded in this paper and cite their sources.
A new series of 2‐substituted‐2,3‐dihydrophthalazine‐1,4‐diones (2‒9) were designed and synthesized to evaluate their anticonvulsant activity. The neurotoxicity was assessed using the rotarod test. Molecular docking was performed for the synthesized compounds to assess their binding affinities as γ‐aminobutyric acid A (GABA‐A) receptor agonists as a possible mechanism of their anticonvulsant action, to rationalize their anticonvulsant activity in a qualitative way. The data obtained from the molecular modeling was strongly matched with that obtained from the biological screening, which revealed that compounds5a,9b, and9hshowed the highest binding affinities toward the GABA‐A receptor and also showed the highest anticonvulsant activities with relative potencies of 1.66, 1.63, and 1.61, respectively, compared with diazepam. The most active compounds5a,9b, and9hwere further tested against maximal electroshock seizures. Compounds5aand9bshowed 100% protection at a dose level of 125 µg/kg, while compound9hexhibited 83.33% protection at the same dose level. A GABA enzymatic assay was performed for these highly active compounds to confirm the obtained results and to explain the possible mechanism for their anticonvulsant action. These agents exerted low neurotoxicity and a high safety margin compared with valproate as a reference drug. Most of our designed compounds exhibited a good ADMET profile.
No takes yet. Share an insight, caveat, or question.
El‐Helby et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: